-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss successful collaborations between academic centers and community practices in the context of (chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, key lessons learned in integrating CAR T therapy into the treatment landscape, and future plans for expanding CAR T therapy’s role in earlier lines of multiple myeloma treatment.
-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.
-
Jan 20, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 20, 2025By Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.
-
Jan 10, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 10, 2025 By Panelists discuss which patients are considered for CAR-T therapy in second-line treatment for relapsed/refractory multiple myeloma (R/R MM) (cilta-cel vs ide-cel), describe the specific criteria and institutional guidelines used to determine patient eligibility, and explore how non-medical factors like such as location and financial considerations impact patient selection, while also outlining the typical CAR-T referral process from community physician outreach to patient...
-
Jan 10, 2025 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
January 10, 2025By Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.
-
Dec 20, 2024 | 
cancernetwork.com | Sagar Lonial |Ajay K. Nooka |Nisha Joseph |Jonathan Kaufman
December 20, 2024By Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.
-
Dec 19, 2023 | 
nature.com | Sara Scott |Ellen Marin |Kathryn T. Maples |Nisha Joseph |Craig C Hofmeister |Vikas Gupta | +3 more
Dear Editor,Teclistamab (Tecvayli®) is a first-in-class T-cell redirecting bispecific antibody that targets CD3 on the surface of T-cells and B-cell maturation antigen (BCMA) on plasma cells [1]. Teclistamab was approved by the FDA for patients with relapsed/refractory multiple myeloma (RRMM) after 4 lines of therapy including an immunomodulatory drug (IMID), proteasome inhibitor (PI), and anti-CD38 monoclonal antibody (mAb) based on the results of the phase 1/2 MajesTEC-1 study.
-
Dec 7, 2023 | 
medscape.org | Luciano Costa |Nisha Joseph
Instructions for Participation & CreditThere are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity.
-
Aug 14, 2023 | 
burrelles.com | Nisha Joseph
Are you interested in guest blogging for the Burrelles Fresh Ideas blog? Email your request to ContentManager[at]burrelles.com, and include your full name, topic idea, business email address, portfolio (or samples) and website (or LinkedIn). Thank you!
-
Aug 2, 2023 | 
cancernetwork.com | Sagar Lonial |Nisha Joseph |Jonathan Kaufman |Ajay K. Nooka
Dr. Sagar Lonial: Alright, let's now shift to case three. Doctor Nooka, you want to take us through case three? Dr. Ajay Nooka: Absolutely. A 66-year-old man with ISS stage three, R-ISS stage three IgG lambda myeloma was diagnosed in 2017. He presented initially with anemia and multiple lytic lesions. The initial FISH results showed a gain of 1q, deletion of 1p, and deletion 13q. Next slide, please.
